MAP2K7 (Phospho-Thr275) Antibody
- Known as:
- MAP2K7 (Phospho-Thr275) Antibody
- Catalog number:
- 11743
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- MAP2K7 (Phospho-Thr275) Antibody
Related genes to: MAP2K7 (Phospho-Thr275) Antibody
- Gene:
- MAP2K7 NIH gene
- Name:
- mitogen-activated protein kinase kinase 7
- Previous symbol:
- PRKMK7
- Synonyms:
- MKK7, Jnkk2
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-04-28
- Date modifiied:
- 2016-10-05
Related products to: MAP2K7 (Phospho-Thr275) Antibody
Related articles to: MAP2K7 (Phospho-Thr275) Antibody
- Pancreatic ductal adenocarcinoma (PDAC) is highly lethal and remains largely refractory to targeted therapy despite its near-universal dependence on oncogenic KRAS. Single-agent KRAS inhibitors often fail due to adaptive resistance mechanisms that emerge under pharmacologic pressure. Previous studies combining MAP2K4 inhibition with KRASG12C-targeted therapy determined that partial JNK suppression can enhance anticancer responses. Here, we extend this concept to PDAC, which is predominantly driven by KRASG12D mutations, and demonstrate that full JNK pathway inactivation restores sensitivity to KRAS inhibition in resistant cells. Using selective MAP2K4, MAP2K7, or combined inhibitors, we show that more extensive JNK suppression disables the feedback loop that reactivates KRAS signaling. In contrast, KRASG12D inhibitor-sensitive cells derive no benefit from JNK pathway inhibition, revealing a resistance-specific vulnerability amenable to therapeutic exploitation. - Source: PubMed
Publication date: 2026/09/07
Connors Gina MPham Thao DBecker Jeffrey HArgus Aria ABaba KenkichiKinoshita TakayoshiMunshi Hidayatullah GScheidt Karl A - Nephrotic syndrome (NS) is a glomerular disorder, with significant morbidity globally. Given the challenge of glucocorticoid resistance, this study aimed to evaluate actionable genetic and epigenetic biomarkers to enable early prediction of therapeutic response. - Source: PubMed
Publication date: 2026/09/28
Almeshary Majid AHussein Dalia TRefaat ManarEl-Refaey Ahmed MEl-Khawaga Omali Y - West Nile virus (WNV) is a mosquito-borne pathogen of escalating epidemiological importance and a growing global health concern, driven by the climate-associated expansion of its mosquito vectors. Although WNV is an extensively studied flavivirus, most host-pathogen interaction studies focus on static and structural aspects rather than dynamic and functional ones. Delineating phosphorylation-mediated interactions between WNV proteins and human kinases bridges a critical gap by providing important insight into the molecular mechanisms underlying infection. In this study, we investigated potential phosphorylation-mediated interactions between WNV proteins and human kinases using an integrative computational framework combining motif prediction, phosphoproteomic data analysis and structural docking. Key interactions were predicted between viral proteins and regulatory kinases within the AKT-ERK pathway and the AMPK-mediated autophagy, including major network kinases such as RAF1, IKBKB, and ULK1. In addition, experimentally validated phosphorylation sites in viral proteins were found to be associated with multiple candidate host kinases, including MAP2K7 and MAP2K9, suggesting complex regulatory networks. Integration with phosphoproteomic datasets supported the relevance of multiple predicted kinases, including those associated with antiviral responses and translational regulation. Protein-protein docking demonstrated stable, energetically favorable interactions between selected host kinases and viral proteins, particularly the viral polymerase (NS5), helicase (NS3), and NS1. The findings of this study establish a framework for future research on the development of host-directed antiviral strategies. - Source: PubMed
Publication date: 2026/07/27
Anil AkashJabbar Ayisha AShaji VineethaAhmed MukhtarJoseph Bristow BenAjayakumar Aromal MonipillilModi Prashant KumarJayanandan AbhithajSoman SowmyaSubbannayya YashwanthRaju Rajesh - Patients with advanced biliary tract cancers (aBTC) are in urgent need of additional treatment options. We aimed to assess the efficacy and safety of ivonescimab plus chemotherapy in patients with aBTC. - Source: PubMed
Publication date: 2026/07/06
Xu QiZhou ShuruiZhang ChenboZhou YiwenHe YatongJiang YvchaoLi JingjingYi TienanLuo CongZhang LeiWu JiaZhang YuhuaWu MinhuaWei QingLi QiLiu BoChen XiangmingYao YinyeYu ChengkunLi JijuanRen YanZhuo WeiYuan LiLi WentingWang Zhongmin MaxwellLi BaiyongXia MichelleXie YanruWu KuiYing Jieer - Breast cancer remains one of the most prevalent malignancies among women, with doxorubicin resistance posing a significant challenge that undermines treatment success and survival outcomes. Aberrant alternative splicing (AS), driven by dysregulation or mutations in splicing factors (SFs), is implicated in cancer initiation, progression, and drug resistance. This study aims to investigate the association of the epithelial cell-specific splicing factor ESRP1 with doxorubicin resistance in breast cancer, focusing on how ESRP1 deficiency correlates with AS changes that promote chemoresistance. - Source: PubMed
Publication date: 2026/06/21
Zhang JingChen LibinSong QinglingXu LiLi YinghuaLi WenWang Jie